يعرض 1,341 - 1,360 نتائج من 12,855 نتيجة بحث عن '(( significant increase decrease ) OR ( significantly ((weaker decrease) OR (greatest decrease)) ))', وقت الاستعلام: 0.54s تنقيح النتائج
  1. 1341
  2. 1342
  3. 1343
  4. 1344
  5. 1345

    Initial participants by wave*. حسب Yeo Ju Sohn (18536198)

    منشور في 2024
    الموضوعات:
  6. 1346
  7. 1347
  8. 1348
  9. 1349
  10. 1350
  11. 1351
  12. 1352
  13. 1353

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  14. 1354

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  15. 1355

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  16. 1356
  17. 1357
  18. 1358
  19. 1359
  20. 1360